149 results
6-K
EX-99.1
MOR
Morphosys AG
30 Apr 24
First Quarter Interim Statement January – March 2024
8:57am
licenses, milestones, and other sources. Research and development expenses in the first quarter of 2024 amounted to € 85.2 million (3M 2023: € 65.4 million … ’ market position Research and Development MorphoSys’ development activities were focused on the following clinical candidates: Pelabresib
6-K
EX-99.1
MOR
Morphosys AG
29 Apr 24
Current report (foreign)
4:15pm
-on-year increase is mainly attributable to higher personnel costs. Research and Development (R&D) Expenses: In the first quarter 2024, R&D expenses were … .
Since February 5, 2024, all research and development activities in connection with tafasitamab are in the responsibility of Incyte, and hence
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
personnel expenses in the financial year 2023.
Research and development expenses decreased by 5%, or EURm 14.2, to EURm 283.6 in the financial year 2023 … .
In the financial year 2023, a goodwill impairment loss of EURm 1.6 was recognized.
Research and Development
Research and development (“R&D”) expenses
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
at 1 N. Waukegan Road North Chicago, 60064 Illinois; the principal business of which is pharmaceutical research and development)
Education … the current shareholder structure of the Bidder as described above:
6.4
Information about Novartis
Novartis is specialized in the research, development, manufacturing
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays
6-K
EX-99.1
i7muntvzbee8ppslb
20 Mar 24
Current report (foreign)
4:12pm
6-K
jhrqqfam6sn8 ap
20 Mar 24
Current report (foreign)
4:12pm
SC14D9C
EX-99.1
bo1l6lcn
15 Mar 24
Written communication relating to third party tender offer
4:46pm
SC14D9C
EX-99.2
7kzk7 16rjhl9lxquws
14 Mar 24
Written communication relating to third party tender offer
4:52pm
6-K
EX-99.1
msr4nyhj2x14p6 ylcp
14 Mar 24
Current report (foreign)
8:27am
6-K
EX-99.2
2wb5pb6593gm i7
14 Mar 24
Current report (foreign)
8:27am
SC14D9C
EX-99.1
5eteija f2gcswyklr0w
13 Mar 24
Written communication relating to third party tender offer
5:22pm
6-K
EX-99.1
hchohuxeu 4xlf2s3n
13 Mar 24
Non-Financial Group Report 2023
4:12pm
6-K
EX-99.1
mp7y9bnf
13 Mar 24
Current report (foreign)
4:08pm
6-K
6n9as8vh hayj5r
13 Mar 24
Current report (foreign)
4:08pm
6-K
EX-99.3
1gj804se 6n
7 Feb 24
MorphoSys Enters into Business Combination Agreement to be
6:57am
6-K
EX-99.2
wl3xp1bkpyn qw
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
kaoozky14a0w1
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
F-3ASR
EX-4.4
bhnwsr 4n86tqx5w12
16 Nov 23
Automatic shelf registration (foreign)
9:27am